Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

NCT05508789 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05508789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05508789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 10, 2022
Completion date
July 31, 2028
Enrollment
1,500 (estimated)
Sites
141

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, brain diseases, central nervous system diseases, dementia, mental disorders, nervous system diseases, neurocognitive disorders, neurodegenerative diseases, tauopathies